1,100 results

#213945-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe4_ChR2_mCherry (#213945). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#135634-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-ChR2-mCherry (#135634). In addition to the viral particles, you will also receive purified pAAV-S5E2-ChR2-mCherry plasmid DNA. Expression of ChR2-mCherry under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 29, 2021

Academic Institutions and Nonprofits only

#137121-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-GCaMP6M (#137121). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Flp recombinase (inhibited in the presence of Cre recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#105541-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.CamKII0.4.eGFP.WPRE.rBG (#105541). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII0.4.eGFP.WPRE.rBG plasmid DNA. Expression of EGFP from CamKII promoter. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Aug. 2, 2018

Academic Institutions and Nonprofits only

#51082-AAV1

Ready-to-use AAV1 particles produced from AAV-EF1a-DIO-GCaMP6s-P2A-nls-dTomato (#51082). In addition to the viral particles, you will also receive purified AAV-EF1a-DIO-GCaMP6s-P2A-nls-dTomato plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under the EF1a promoter. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

Sept. 19, 2017

Academic Institutions and Nonprofits only

#104496-PHPeB

Ready-to-use AAV PHP.eB particles produced from pGP-AAV-CAG-FLEX-jGCaMP7f-WPRE (#104496). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7f-WPRE plasmid DNA. CAG-driven, Cre-dependent jGCaMP7f calcium sensor. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Sept. 27, 2023

Academic Institutions and Nonprofits only

#45580-AAV1

Ready-to-use AAV1 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

Nirao Shah, Jim Wells

Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

Dec. 3, 2020

Academic Institutions and Nonprofits only

#137127-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-sRGECO (#137127). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-sRGECO plasmid DNA. EF1a-driven, Cre-dependent expression of cytosolic sRGECO calcium sensor (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 18, 2021

Academic Institutions and Nonprofits only

#137124-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-GCaMP6F (#137124). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-GCaMP6F plasmid DNA. EF1a-driven, Flp-dependent expression of GCaMP6f (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 18, 2021

Academic Institutions and Nonprofits only

#107738-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn-Cre-P2A-dTomato (#107738). In addition to the viral particles, you will also receive purified pAAV-hSyn-Cre-P2A-dTomato plasmid DNA. hSyn-driven expression of Cre and dTomato (physically separate). These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

June 1, 2020

Academic Institutions and Nonprofits only

#213815-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe10_ChR2_mCherry (#213815). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E10. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#214147-AAV5

Ready-to-use AAV5 particles produced from pAAV-hIBA1a-GFP-miR124T (#214147). In addition to the viral particles, you will also receive purified pAAV-hIBA1a-GFP-miR124T plasmid DNA. hIBA1a-driven and miR124T-targeted for microglial inhibition of GFP. These AAV preparations are suitable purity for injection into animals.

Chun-Li Zhang

Serrano et al iScience. 2024 Aug 12;27(9):110706. doi:

Sept. 22, 2025

Academic Institutions and Nonprofits only

#175274-AAV1

Ready-to-use AAV1 particles produced from pAAV-rtTA (#175274). In addition to the viral particles, you will also receive purified pAAV-rtTA plasmid DNA. Syn-driven expression of reverse tetracycline-controlled transactivator. These AAV preparations are suitable purity for injection into animals.

Wei Xu

Li et al Nat Methods. 2021 Nov 25. pii: 10.1038/s

Jan. 15, 2026

Academic Institutions and Nonprofits only

#55641-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Sept. 27, 2023

Academic Institutions and Nonprofits only

#50469-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-EGFP (#50469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-EGFP plasmid DNA. CamKIIa-driven EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#105552-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.hSyn.TurboRFP.WPRE.RBG (#105552). In addition to the viral particles, you will also receive purified pENN.AAV.hSyn.TurboRFP.WPRE.RBG plasmid DNA. hSynapsin-driven TurboRFP. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 25, 2018

Academic Institutions and Nonprofits only

#100841-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.GCaMP6m.WPRE.SV40 (#100841). In addition to the viral particles, you will also receive purified pAAV.Syn.GCaMP6m.WPRE.SV40 plasmid DNA. Syn-driven GCaMP6m calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 16, 2018

Academic Institutions and Nonprofits only

#179460-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-DIO-JEDI-2P-WPRE (#179460). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-JEDI-2P-WPRE plasmid DNA. EF1a-driven, Cre-dependent expression of voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Aug. 22, 2022

Academic Institutions and Nonprofits only

#105537-AAV2

Ready-to-use AAV2 particles produced from pENN.AAV.CMVs.Pl.Cre.rBG (#105537). In addition to the viral particles, you will also receive purified pENN.AAV.CMVs.Pl.Cre.rBG plasmid DNA. CMV-driven Cre. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Sept. 18, 2018

Academic Institutions and Nonprofits only

#26966-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only